Accessibility StatementSkip Navigation SAN DIEGO, Oct. 17, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of a new post-hoc analysis from the Phase 3, open-label KINECT 4 study, demonstrating that patients treated continuously for 48 weeks with the 40 mg dose of once-daily INGREZZA (valbenazine) capsules experienced clinically meaningful improvements in tardive dyskinesia symptoms. Findings will be presented at the American Psychiatric Nurses Association ...